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AbsTrACT
Objectives the objective of this study was to compare the 
prevalence of polydrug use, use of drugs associated with 
chemsex, specific drug use, and HiV-related behaviours, 
between two time periods , using two groups of HiV-
negative men who have sex with men (MSM) attending the 
same sexual health clinics in london and Brighton, in two 
consecutive periods of time from 2013 to 2016.
Methods Data from MSM in the cross-sectional 
attitudes to and Understanding risk of acquisition of 
HiV (aUraH) study (June 2013 to September 2014) were 
compared with baseline data from different MSM in the 
prospective cohort study attitudes to and Understanding 
risk of acquisition of HiV over time (aUraH2) 
(november 2014 to april 2016). Prevalence of polydrug 
use, drug use associated with chemsex and specific 
drug use, and 10 measures of HiV-related behaviours 
including condomless sex, post-exposure prophylaxis 
(PeP) use, pre-exposure prophylaxis (PreP) use, and HiV 
testing, were compared. Prevalence ratios (Prs) for the 
association of the study (time period) with drug use and 
HiV-related behaviour measures were estimated using 
modified Poisson regression analysis, unadjusted and 
adjusted for sociodemographic factors.
results in total, 991 MSM were included from aUraH 
and 1031 MSM from aUraH2. after adjustment for 
sociodemographic factors, use of drugs associated with 
chemsex had increased (adjusted Pr (aPr) 1.30, 95% ci 
1.11 to 1.53) and there were prominent increases in 
specific drug use; in particular, mephedrone (aPr 1.32, 
95% ci 1.10 to 1.57), γ-hydroxybutyric/γ-butryolactone 
(aPr 1.47, 95% ci 1.15 to 1.87) and methamphetamine 
(aPr 1.42, 95% ci 1.01 to 2.01). Use of ketamine had 
decreased (aPr 0.54, 95% ci 0.38 to 0.78). certain 
measures of HiV-related behaviours had also increased, 
most notably PeP use (aPr 1.50, 95% ci 1.21 to 1.88) 
and number of self-reported bacterial Sti diagnoses (aPr 
1.24, 95% ci 1.08 to 1.43).
Conclusions there have been significant increases in 
drug use associated with chemsex and some measures 
of HiV-related behaviours among HiV-negative MSM 
in the last few years. changing patterns of drug use 
and associated behaviours should be monitored to 
enable sexual health services to plan for the increasingly 
complex needs of some clients.
InTrOduCTIOn
The use of recreational drugs by gay and bisexual 
men who have sex with men (MSM) in the UK is 
significantly higher than in the male population in 
general.1 Along with alcohol and tobacco use,2 recre-
ational drug use and its complex relationship with 
sexual risk behaviour3–5 and the potential to facilitate 
HIV6 7 and STI transmission8 9 may have a broader 
impact on the health and well-being of gay men.10 11 
The emerging phenomenon of chemsex (defined in 
the UK as the use of mephedrone, crystal meth-
amphetamine and γ-hydroxybutyric/γ-butryolac-
tone (GHB/GBL) to enable, enhance and prolong 
sexual interactions12) is described predominantly 
within the MSM community, and, although chemsex 
drug use is not always problematic,13 issues relating 
to it have received increasing academic12 14 and 
clinical15–17 attention. The interest is mainly driven 
by the strong associations with high-risk sexual 
behaviour5 17 and other potential harms such as 
overdose and death.18 Data from some sexual health 
clinics suggest there has been a rapid rise in chemsex 
drug use by MSM attending STI clinics within the 
last few years,9 19 both in and out of major conur-
bations,20 and chemsex has become a considerable 
public health concern. Public Health England’s 
2015/2016 action plan to promote the health and 
well-being of MSM2 and the UK government 2017 
Drug Strategy21 both target chemsex and aim to 
reduce it; however, current evidence on prevalence 
of chemsex drug use is limited, as is the impact 
chemsex drug use may have on sexual behaviour.
In this paper, we use cross-sectional question-
naire data from two studies that recruited HIV-neg-
ative or HIV-undiagnosed MSM from sexual health 
clinics in England, the Attitudes to and Under-
standing Risk of Acquisition of HIV (AURAH) study 
(June 2013 to September 2014),22 and the AURAH2 
(Attitudes to and Understanding Risk of Acquisition 
of HIV over Time) study (November 2014 to April 
2016).23 We assess the prevalence and use of poly-
drugs, drugs associated with chemsex and specific 
drug use, and HIV-related behaviours, among the 
AURAH study participants5 and compare it with 
a different set of participants from the AURAH2 
study at a different time period.
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MeThOds
The AURAH study is a cross-sectional, clinic-based study that 
recruited HIV-negative or undiagnosed participants from sexual 
health clinics across England between June 2013 and September 
2014.22 Participants completed a self-administered confiden-
tial paper questionnaire on demographics (gender, sexual iden-
tity, age, ethnicity, UK birth, English fluency), socioeconomic 
factors (education, employment, housing, money for basic 
needs), health and lifestyle factors (alcohol use, smoking, symp-
toms of depression, treatment for depression and other mental 
illness), as well as recent sexual behaviour (past 3 months), and 
recent recreational drug use (past 3 months), while waiting for 
their clinic appointment (participants were offered a private 
room if preferred).
The AURAH2 study is a prospective cohort study that recruited 
HIV-negative or undiagnosed MSM from three of the same sexual 
health clinics (two in London, one in Brighton)23 that partici-
pated in the AURAH study. The AURAH2 study used the same 
paper questionnaire as the AURAH study to collect baseline data, 
in clinic, during the recruitment period from November 2014 to 
April 2016. Participants then completed subsequent 4-monthly 
and annual online questionnaires on HIV status, health and 
lifestyle factors (including recreational drug use and chemsex) 
and recent sexual behaviour. Online follow-up of participants 
continued for 3 years until March 2018 and did not necessitate 
a clinic visit. Methodological details for both studies, including 
response rates, have been published elsewhere.22 23
This paper uses data collected from the AURAH study and the 
baseline questionnaire of the AURAH2 study, from MSM aged 
over 18 and HIV negative (or undiagnosed at recruitment) who 
attended the three sexual health clinics in England that partici-
pated in both the AURAH and the AURAH2 studies: 56 Dean 
Street, London; Mortimer Market Clinic, London; Claude Nicol 
Centre, Brighton. Individuals who participated in both studies 
were only included in the AURAH study analysis for this paper.
Ascertainment of recreational drug use
All participants were asked to self-report whether they had used 
recreational drugs in the last 3 months and, if so, to select which 
drug or drugs from the following list: acid/LSD/magic mush-
rooms, anabolic steroids, cannabis (marijuana, grass), cocaine 
(coke), crack, codeine, crystal meth (methamphetamine), ecstasy 
(E), GHB/GBL (liquid ecstasy), heroin, ketamine (K), khat 
(chat), mephedrone, morphine, opium, poppers (amyl nitrate), 
speed (amphetamine), Viagra and Other. If a participant selected 
‘Other’, there was space for free text and a request to specify the 
name(s) of the drug(s).
recreational drug use definition
Two measures of recreational drug use were defined: (1) poly-
drug use, use of three or more recreational drugs at any time in 
the past 3 months; (2) drugs associated with chemsex, use of one 
or more of mephedrone, crystal meth or GHB/GBL in the past 
3 months. It should be noted that the questionnaire did not ask 
about drug use during sex specifically.
hIV-related behaviours
Ten measures of HIV-related behaviours and related activities 
were derived from the questionnaire. Four measures of condom-
less sex (CLS) in the past 3 months were defined as (1) CLS 
with one or more partners, (2) CLS with two or more partners, 
(3) CLS with partners of unknown or HIV-positive partners 
(excluding long-term HIV-positive partners with whom they 
thought the risks of catching HIV were low because their partner 
was on antiretroviral therapy) and (4) receptive CLS with an 
HIV unknown status partner. Six additional measures related to 
sexual behaviour: (5) diagnosis with a bacterial STI in the past 
year (gonorrhoea, chlamydia, syphilis and/or lymphogranuloma 
venereum), (6) more than 11 sexual partners (past year), (7) 
group sex (in the past 3 months), (8) post-exposure prophylaxis 
(PEP) use (past year), (9) pre-exposure prophylaxis (PrEP) use 
(past year) and (10) recent HIV test (past 6 months). CLS refers 
to anal sex and, for MSM who self-reported their sexuality as 
bisexual, vaginal sex.
statistical analysis
Prevalence of polydrug use, drug use associated with chemsex 
and specific drug use between the AURAH and AURAH2 study 
were assessed, with and without adjustment for sociodemo-
graphic factors, and results are shown as unadjusted and adjusted 
prevalence ratios (aPRs). Prevalence of HIV-related behaviours 
between the two studies (time periods) was then compared with 
and without adjustment for the same factors. All the multivari-
able models were adjusted for sociodemographic factors: age (as 
a continuous variable), ethnicity (born/not born in the UK and 
white/non-white ethnicity), education (educated to university 
level or not), sexual identity (gay or bisexual/other) and rela-
tionship status (ongoing relationship or not), to produce aPRs 
using modified Poisson regression analysis.24 All analysis was 
conducted in Stata statistical software V.13.25 These models 
were applied to subjects with no missing values for all the vari-
ables included in the model. In sensitivity analyses, we treated 
missing values as separate categories and applied the models to 
all subjects in the study.
An additional analysis was undertaken to assess the associa-
tion of drug use measures with HIV-related behaviours among 
a restricted sample of AURAH2 MSM that reported anal (or 
vaginal) sex in the past 3 months to specifically compare those 
having condom protected sex with those having CLS and the asso-
ciations with polydrug use and drugs associated with chemsex. 
The multivariable models were adjusted for (1) the sociodemo-
graphic factors outlined above and (2) sociodemographic factors 
plus higher risk drinking (WHO AUDIT-C (Alcohol Use Disor-
ders Identification Test-C) score ≥6) and depressive symptoms 
PHQ-9 (Patient Health Questionnaire-9) total score ≥10).
resulTs
Participant characteristics
In 2013/2014, 1484 MSM participated in the AURAH study. The 
response rate was 60.0%.22 Of these, 991 MSM attended the same 
three clinics that took part in the AURAH2 study. There were 
1031 individuals who participated in the AURAH2 study with a 
response rate of 51.2%. In total, 136 individuals participated in 
both the AURAH and AURAH2 studies and were excluded from 
the AURAH2 sample for this analysis. Table 1 compares the char-
acteristics of the 991 MSM in the AURAH study with the 1031 
MSM who participated in the AURAH2 study. The participant 
characteristics in both studies were similar: the large majority 
were white (AURAH 81.0%, AURAH2 80.5%), self-identified as 
gay (AURAH 89.9%, AURAH2 92.7%), financially stable (always 
having money to cover basic needs; AURAH 74.4%, AURAH2 
76.6%), educated to university degree level (AURAH 71.3%, 
AURAH2 74.6%) and employed (AURAH 80.2%, AURAH2 
82.6%) (table 1). The main significant difference between the 
two studies was the higher proportion of younger MSM (<25 
years) in the AURAH2 study (AURAH 14.8%, AURAH2 24.5%).
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Table 1 Sociodemographic and lifestyle factors of MSM participants in the AURAH and AURAH2 studies
Category Classification AurAh n=991 MsM n (%) (95% CI) AurAh2 n=1031 MsM n (%) (95% CI) P value*
Age (years) <25 147 (14.8%) (12.8% to 17.2%) 253 (24.5%) (22.0% to 27.3%)
<0.001
25–29 244 (24.6%) (22.0% to 27.4%) 183 (17.7%) (15.5% to 20.2%)
30–34 197 (19.9%) (17.5% to 22.5%) 205 (19.9%) (17.5% to 22.4%)
35–39 128 (12.9%) (10.9% to 15.1%) 139 (13.5%) (11.5% to 15.7%)
40–44 103 (10.4%) (8.6% to 12.4%) 105 (10.1%) (8.4% to 12.1%)
45+ 160 (16.2%) (13.9% to 18.6%) 139 (13.4) (11.5% to 15.7%)
Missing 12 (1.2%) (0.7% to 2.1%) 7 (0.7%) (0.3% to 1.4%)
Born in the UK and  
white ethnicity
Yes, white 493 (49.8%) (46.6% to 52.8%) 494 (47.9%) (44.9% to 50.9%)
0.543
Yes, non-white 57 (5.7%) (4.4% to 7.4%) 55 (5.3%) (4.1% to 6.8%)
No, white 309 (31.2%) (28.4% to 38.1%) 336 (32.6%) (29.7% to 35.5%)
No, non-white 120 (12.1%) (10.2% to 14.3%) 139 (13.5%) (11.5% to 15.7%)
Missing 12 (1.2%) (0.7% to 2.1%) 7 (0.7%) (0.3% to 1.4%)
Self-reported sexuality Gay 891 (89.9%) (87.7% to 91.6%) 956 (92.7%) (90.9% to 94.1%)
0.005Bisexual/other 97 (9.8%) (8.1% to 11.8%) 66 (6.4%) (5.1% to 8.1%)
Missing 3 (0.3%) (0.09% to 0.9%) 9 (0.9%) (0.4% to 1.6%)
Money to cover basic needs All of the time 737 (74.4%) (71.5% to 76.9%) 789 (76.6%) (73.8% to 79.0%)
0.432
Most of the time 199 (20.1%) (17.7% to 22.7%) 180 (17.4) (15.3% to 19.9%)
Sometimes/no 53 (5.3%) (4.1% to 6.9%) 61 (5.9) (4.6% to 7.5%)
Missing 2 (0.2%) (0.05% to 0.8%) 1 (0.1%) (0.01% to 0.6%)
University education Yes 706 (71.3%) (68.3% to 73.9%) 769 (74.6%) (71.8% to 77.2%)
0.238No 284 (28.6%) (25.9% to 31.5%) 261 (25.3%) (22.7% to 28.1%)
Missing 1 (0.1%) (0.01% to 0.7%) 1 (0.1%) (0.01% to 0.6%)
Employed Yes 795 (80.2%) (77.6% to 82.6%) 852 (82.6%) (80.2% to 84.8%)
0.293No 184 (18.6%) (16.3% to 21.1%) 171 (16.6%) (14.4% to 18.9%)
Missing 12 (1.2%) (0.6% to 2.1%) 8 (0.8%) (0.3% to 1.5%)
Housing status Home owner 284 (28.6%) (25.9% to 31.5%) 272 (26.6%) (23.7% to 29.1%)
0.51
Renting 565 (57.0%) (53.9% to 60.1%) 610 (59.8%) (56.1% to 62.1%)
Unstable/other 128 (12.9%) (10.9% to 15.2%) 139 (13.6%) (11.5% to 15.7%)
Missing 14 (1.4%) (0.8% to 2.3%) 10 (0.9%) (0.5% to 1.7%)
Ongoing relationship status Yes 422 (42.5%) (39.5% to 45.7%) 412 (39.9%) (37.0% to 42.9%)
0.231No 569 (57.4%) (54.3 % to 60.5 %) 618 (59.9%) (57.0 % to 62.9 %) 
Missing 0 1 (0.1%) (0.01 % to 0.6 %) 
Higher-risk alcohol 
 consumption  
(WHO AUDIT ≥6)†
Yes 121 (12.2%) (10.3% to 14.4%) 93 (9.0%) (7.4% to 10.9%)
0.061No 865 (87.3%) (85.1% to 89.2%) 933 (90.5%) (88.5% to 92.1%)
Missing 5 (0.5%) (0.2% to 1.2%) 5 (0.5%) (0.2% to 1.1%)
Clinically significant  
depressive symptoms  
(PHQ-9 score ≥10) ‡
Yes 109 (11%) (9.1% to 13.1%) 128 (12.4%) (10.5% to 14.5%)
0.322No 882 (89%) (86.9% to 90.8%) 903 (87.6%) (85.4% to 89.4%)
Clinically significant  
anxiety symptoms  
(GAD7** score ≥10)‡
Yes 86 (8.7%) (7.1% to 10.6%) 118 (11.4%) (9.6% to 13.5%)
0.039No 905 (91.3%) (89.4% to 92.9%) 913 (88.6%) (86.5% to 90.3%)
*P value by χ2 test or Fisher’s exact test where appropriate.
†Higher-risk drinking is based on the first three questions of the WHO AUDIT-C questionnaire. Higher-risk drinking is indicated by a score of ≥6 and lower-risk drinking/no alcohol 
consumption by a score of <6 .
‡All included participants completed at least one answer in this section of the questionnaire, providing a minimum score of at least 1.
* * GAD7 (Generalised Anxiety Disorder-7)
AURAH, Attitudes to and Understanding Risk of Acquisition of HIV; AURAH2, Attitudes to and Understanding Risk of Acquisition of HIV over Time; MSM, men who have sex with 
men.
Changes over time in recreational drug use
Overall, a greater proportion of MSM in the AURAH2 study 
reported use of one or more recreational drug(s) in the past 
3 months (AURAH 57.4%, AURAH2 60.4%). Figure 1 shows 
the proportion of MSM reporting polydrug use, the use of drugs 
associated with chemsex, and specific, individual drugs used 
in the AURAH and AURAH2 study. There was an increase in 
polydrug use from the AURAH to AURAH2 study (PR 1.19, 
95% CI 1.04 to 1.37, P=0.01); however, after adjustment for 
sociodemographic factors, the increase did not persist (aPR 
1.16, 95% CI 0.99 to 1.37, P=0.07). The use of drugs associated 
with chemsex had significantly increased by about a third from 
AURAH to AURAH2, and this increase remained significant after 
adjustment for sociodemographic factors (aPR 1.30, 95% CI 
1.11 to 1.53, P=0.002) (see figure 1).
Across both studies, the most commonly used drug was nitrites 
(AURAH 35.2%, AURAH2 36.3%) (figure 1). The prevalence 
of cocaine use (AURAH 21.5%, AURAH2 23.9%), cannabis 
(AURAH 20.9%, AURAH2 20.1%) and MDMA (AURAH 14.1%, 
AURAH2 14.5%) was similar between the two studies (figure 1).
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Figure 1 Prevalence of polydrug use, drug use associated with chemsex and individual drug use in MSM participants in the Attitudes to and 
Understanding Risk of Acquisition of HIV (AURAH, 2013-14) and Attitudes to and Understanding Risk of Acquisition of HIV over Time (AURAH2, 2014-
16) studies. 
The most prominent increases in the use of specific drugs 
were seen in drugs associated with chemsex; mephedrone use 
had increased by about a third (aPR 1.32, 95% CI 1.10 to 1.57), 
GHB/GBL by nearly half (aPR 1.47, 95% CI 1.15 to 1.87) and 
methamphetamine use had increased by nearly half (aPR 1.42, 
95% CI 1.01 to 2.01). In fact, use of nearly all types of specific 
drugs had increased in the AURAH2 study with the exception 
of ketamine, which had decreased (aPR 0.54, 95% CI 0.38 to 
0.78), while cannabis and 'other drugs' (heroin, crack cocaine, 
opium, morphine, khat, codeine, acid) remained at roughly the 
same prevalence. The proportion of MSM who reported use 
of drugs associated with chemsex, while still a minority, had 
increased from the AURAH to AURAH2 study for all three drugs 
commonly associated with chemsex: mephedrone from 20.9% 
to 28.8%, GHB/GBL from 13.1% to 19.8% and methampheta-
mine 6.6% to 9.8% (see figure 1).
Changes over time in hIV-related behaviours
Some measures of HIV-related behaviours had increased to 
various extents in the AURAH2 study compared with the AURAH 
study (CLS, CLS 2+ partners, STI, PEP, PreP, HIV testing), and 
most of these remained statistically significant after adjusting for 
sociodemographic factors (table 2).
The results were very similar when missing values for all the 
variables included in the model were treated as separate catego-
ries and applied (see online supplementary table 4).
The largest differences among the measures of HIV-related 
behaviours between the AURAH and AURAH2 study was in PEP 
use (past year), which had increased by over 40% (aPR 1.50, 
95% CI 1.21 to 1.88), and the number of self-reported bacte-
rial STI diagnoses (past year), which had increased by a quarter 
(aPR 1.24, 95% CI 1.08 to 1.43). There was also an increase 
in the proportion of men who had recently tested for HIV in 
the AURAH2 study, which remained significant after adjustment 
for study and sociodemographic factors (aPR 1.14, 95% CI 
1.07 to 1.21).
relationship between recreational drug use and hIV-related 
behaviours
Table 3 shows the associations of polydrug use and drug use 
associated with chemsex, with HIV-related behaviour measures 
among the subgroup of MSM who reported anal (or vaginal) sex 
within the past 3 months (n=949) in the AURAH2 study. Similar 
to the AURAH study results,5 in AURAH2, polydrug and drug 
use associated with chemsex use remained strongly associated 
with all measures of HIV-related behaviours, with the exception 
of receptive CLS with unknown status partner, in (1) unadjusted, 
(2) adjusted for study, age, ethnicity, sexual identity, university 
education and ongoing relationship status, and (3) adjusted for 
study, sociodemographic factors plus additional, higher-risk 
drinking and depressive symptoms.
dIsCussIOn
We observed substantial increases over the 3-year period from 
the AURAH to AURAH2 study in the use of drugs associated 
with chemsex  and specific drug use, as well as increases in 
some measures of HIV-related behaviours, including condom-
less sex, PEP, - and HIV testing . The most notable increase 
was the prevalence of drugs associated with chemsex (AURAH: 
24.2% vs AURAH2: 32.3%), driven by the considerable indi-
vidual increases in mephedrone, methamphetamine and GHB/
GBL. Certain measures of HIV-related behaviours had also 
increased, including CLS with one or more partners, which may 
partly explain the increase in self-reported bacterial STI diagnosis 
from the AURAH to AURAH2 study (30.5% vs 3%). Encourag-
ingly, there was also an increase in the number of MSM who 
reported an HIV test in the past 6 months (63.8% vs 73.4%), in 
line with increasing ever and repeat HIV testing in MSM in the 
UK over the same time period.26
To our knowledge, the AURAH and AURAH2 studies are the 
largest studies within the UK to have investigated prevalence 
of recreational drug use and HIV-related behaviours among 
HIV-negative MSM attending sexual health clinics. The prev-
alence of recreational and specific drug use in our results from 
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Table 2 Prevalence of HIV-related behaviours among men who have sex with men in the Attitudes to and Understanding Risk of Acquisition of 
HIV (AURAH) (n=991) and Attitudes to and Understanding Risk of Acquisition of HIV over Time (AURAH2) (n=1031) studies and association of these 
measures with  study
Measures of sexual behaviour study Prevalence n (%) (95% CI)
unadjusted Pr (95% CI)
AurAh2 vs AurAh* P value† Adjusted‡ Pr (95% CI) P value† 
CLS with one or more partners  
(past 3 months)
AURAH 558 (56.3%) (53.3% to 59.4%) 1.14 (1.07 to 1.23) <0.001 1.14 (1.05 to 1.24)
0.001
AURAH2 664 (64.4%) (61.5% to 67.4%)
CLS with two or more partners  
(past 3 months)
AURAH 286 (28.8%) (26.1% to 31.8%) 1.22 (1.08 to 1.39) 0.002 1.22 (1.05 to 1.41)
0.008
AURAH2 365 (35.4%) (32.5% to 38.4%)
CLS with unknown/HIV+ status 
partner(s) (past 3 months)
AURAH 310 (31.3%) (28.5% to 34.3%) 1.00 (0.88 to 1.14) 0.944 0.99 (0.85 to 1.14)
0.893
AURAH2 324 (31.4%) (28.7% to 34.3%)
Receptive CLS with unknown HIV 
status partner(s) (past 3 months)
AURAH 116 (11.7%) (9.8% to 13.8%) 1.06 (0.84 to 1.34) 0.624 0.98 (0.75 to 1.28)
0.901
AURAH2 128 (12.4%) (10.5% to 14.6%)
Self-reported bacterial STI 
diagnosis (past year)
AURAH 303 (30.5%) (27.8% to 33.5%) 1.30 (1.15 to 1.47) <0.001 1.24 (1.08 to 1.43)
0.002
AURAH2 411 (39.8%) (36.9% to 42.9%)
Eleven or more new sexual  
partners (past year)
AURAH 374 (37.7%) (34.8% to 40.1%) 1.07 (0.97 to 1.20) 0.168 1.11 (0.98 to 1.25)
0.09
AURAH2 420 (40.7%) (37.8% to 43.7%)
Group sex (past 3 months) AURAH 388 (39.1%) (36.2% to 42.2%) 1.10 (0.99 to 1.22) 0.069 1.10 (0.97 to 1.24)
0.08
AURAH2 438 (42.5%) (39.5% to 45.5%)
PEP use (past year) AURAH 151 (15.2%) (13.1% to 17.6%) 1.43 (1.18 to 1.72) <0.001 1.50 (1.21 to 1.88)
<0.001
AURAH2 224 (21.7%) (19.3% to 24.4%)
PrEP use (past year) AURAH 38 (3.8%) (2.5% to 4.5%) 1.44 (0.96 to 2.15) 0.074 1.31 (0.70 to 1.82)
0.611
AURAH2 57 (5.5%) (4.3% to 7.1%)
Recent HIV test (past 6 months) AURAH 631 (63.8%) (60.7% to 66.7%) 1.15 (1.09 to 1.22) <0.001 1.14 (1.07 to 1.21)
<0.001
AURAH2 757 (73.4%) (70.6% to 76.0%)
*AURAH is the reference group.
†P value by Wald test.
‡Adjusted model (ii) study, age (continuous variable), ethnicity, sexual identity, university education, ongoing relationship status (Poisson model on subject with no missing 
values for all the variables included in the model).
AURAH, Attitudes to and Understanding Risk of Acquisition of HIV; AURAH2, Attitudes to and Understanding Risk of Acquisition of HIV over Time; CLS, condomless sex; PEP, post-
exposure prophylaxis; PR, prevalence ratio; PrEP, pre-exposure prophylaxis.
the AURAH study is similar to that reported by other high-in-
come countries from the same calendar years,27 28 however 
the AURAH2 study results provide a more recent estimate. In 
Australia, baseline analysis on the first entirely online cohort 
study of MSM (Following Lives Undergoing Change (Flux) study) 
(n=2250) recruited in 2014/2015, found that over half (50.5%) 
had reported use of any illicit drug in the previous 6 months, and 
over a quarter (28%) had used party drugs (E, speed, cocaine, 
crystal methamphetamine, GHB, ketamine, LSD) in the previous 
6 months.27 Trends in drug use among Australian gay men are 
also monitored in routinely conducted behavioural surveillance 
surveys, ‘the Gay Community Periodic Surveys’, which suggest 
little change in recent years.29 A similar- prevalence (55.7%) was 
reported among HIV-negative MSM in the USA by the National 
HIV Behavioural Surveillance survey conducted in the same year 
as the AURAH and Flux studies (2014),28 and this has steadily 
increased among MSM (regardless of HIV status) from 43% in 
2004/200530 to 49% in 2011,31 to 55.7%28 in 2014. As demon-
strated by the changes in prevalence and patterns of drug use and 
associated behaviours over time in our results, the monitoring 
of recreational drug use in MSM is vital if service providers, 
including sexual health, HIV and drug use services, are to antici-
pate and plan for the needs of their clients, whilst a better under-
standing of factors that may facilitate the use of drugs within a 
sexual setting, such as geospatial networking apps,32 is needed. 
Furthermore, longitudinal monitoring could help identify trends 
that may be hidden when examining prevalences in cross-sec-
tional surveys.
A recent steep decline in HIV diagnoses has been reported in 
two of the London clinics from which the AURAH and AURAH2 
studies recruited,26 despite an increase in HIV testing. The 
decline in HIV incidence has been attributed to a combination of 
prevention interventions, particularly testing followed by rapid 
initiation of HIV treatment, and the use of PrEP (despite not 
being freely available).26 Self-reported PrEP use was relatively 
low in in both AURAH (3.8%) and AURAH2 (5.5%), although 
it is likely to have increased since the collection of the AURAH2 
baseline. In the USA, where PrEP has been available since 2012, 
HIV-negative MSM substance users were identified as a high-
risk trajectory group that would benefit from access to PrEP,33 
and our results indicate that this is similar in the UK. While the 
effect of wider access to PrEP on sexual behaviour and recrea-
tional drug use is yet unknown, our results show an increasing 
trend in certain measures of HIV-related behaviours and poly-
drug and recreational drug use in a context where PrEP is not 
freely available.
MSM who use recreational drugs, particularly in the context 
of chemsex, may not see themselves as ‘typical’ drug misusers 
or consider the use of chemsex drugs to be problematic and 
are therefore unlikely to access traditional drug services.32 
Equally, these services may not be trained to deal with the 
specific needs of this population.15 The large numbers of MSM 
reporting polydrug use and drugs associated with chemsex in 
the AURAH and AURAH2 studies, along with the high propor-
tions of PEP use, STI infection and clinically significant depres-
sion and anxiety symptoms, highlight the complex needs of this 
population and support the view that sexual health services need 
to provide holistic clinical assessment and care, including drug 
services, to improve health and well-being in an acceptable envi-
ronment for MSM.16 17
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Table 3 Associations of polydrug use and drug use associated with chemsex, with measures of HIV-related behaviours, among 949 MSM in the 
AURAH2 study who reported anal or vaginal sex in the past 3 months
hIV-related behaviour 
outcome 
Poly drug use (past 3  months) Chemsex drug use (past 3 months)
unadjusted
Pr (95% CI)
P value*
Adjusted (i)
Pr (95% CI)
P value*
Adjusted (ii)
Pr (95% CI)
P value*
unadjusted
Pr (95% CI)
P value*
Adjusted (i)
Pr (95% CI)
P value*
Adjusted (ii)
Pr (95% CI)
P value*
CLS with one or more 
partners (past 3 months) 
1.30 (1.20 to 1.40) 1.31 (1.21 to 1.42) 1.31 (1.21 to 1.41) 1.32 (1.23 to 1.43) 1.33 (1.23 to 1.44) 1.33 (1.23 to 1.44)
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
CLS with two or more 
partners (past 3 months) 
1.91 (1.64 to 2.24) 1.93 (1.65 to 2.25) 1.91 (1.63 to 2.23) 1.95 (1.67 to 2.28) 1.95 (1.67 to 2.28) 1.94 (1.66 to 2.27)
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
CLS with unknown/HIV-
positive partner  
(past 3 months) 
1.71 (1.44 to 2.03) 1.69 (1.43 to 2.02) 1.71 (1.43 to 2.03) 1.83 (1.54 to 2.17) 1.81 (1.52 to 2.16) 1.82 (1.53 to 2.16)
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Receptive CLS with 
unknown status partner 
(past 3 months)
1.37 (0.98 to 1.89) 1.34 (0.97 to 1.87) 1.34 (0.97 to 1.85) 1.36 (0.98 to 1.89) 1.34 (0.97 to 1.86) 1.34 (0.97 to 1.85)
0.062 0.07 0.08 0.07 0.08 0.08
Bacterial STI diagnosis 
(past year)
1.65 (1.43 to 1.91) 1.66 (1.44 to 1.91) 1.66 (1.43 to 1.91) 1.69 (1.43 to 1.91) 1.66 (1.43 to 1.91) 1.65 (1.43 to 1.91)
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Eleven or more new 
sexual partners  
(past year)
1.64 (1.43 to 1.89) 1.62 (1.41 to 1.86) 1.61 (1.39 to 1.85) 1.61 (1.39 to 1.85) 1.56 (1.36 to 1.79) 1.55 (1.35 to 1.78)
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Group sex  
(past 3 months)
2.41 (2.11 to 2.75) 2.38 (2.08 to 2.72) 2.38 (2.09 to 2.73) 2.39 (2.09 to 2.75) 2.39 (2.09 to 2.74) 2.39 (2.09 to 2.74)
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
PEP use (past year) 
2.16 (1.72 to 2.71) 2.15 (1.71 to 2.71) 2.16 (1.72 to 2.72) 2.47 (1.95 to 3.11) 2.43 (1.93 to 3.08) 2.44 (1.93 to 3.08)
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
PrEP use (past year)
2.46 (1.49 to 4.01) 2.54 (1.54 to 4.19) 2.69 (1.64 to 4.43) 2.13 (1.29 to 3.52) 2.28 (1.39 to 3.71) 2.38 (1.46 to 3.86)
<0.001 <0.001 <0.001 0.003 0.001 <0.001
Recent HIV test (within 
past 6 months)
1.16 (1.08 to 1.25) 1.16 (1.08 to 1.25) 1.17 (1.09 to 1.26) 1.18 (1.10 to 1.26) 1.18 (1.10 to 1.27) 1.18 (1.11 to 1.27)
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Adjusted model (i) age (continuous variable), ethnicity, sexual identity, university education, ongoing relationship status.
Adjusted model (ii) age (continuous variable), ethnicity, sexual identity, university education, ongoing relationship status, higher-risk drinking, depressive symptoms (PHQ-9 ≥10) (missing values 
included in variables for adjusted models).
*P values by Wald test. 
 AURAH2, Attitudes to and Understanding Risk of Acquisition of HIV over Time; CLS, condomless sex; MSM, men who have sex with men; PEP, post-exposure prophylaxis; PrEP, pre-exposure 
prophylaxis. 
Key messages
 ► Use of drugs associated with chemsex has substantially 
increased among HIV-negative men who have sex with men 
attending sexual health clinics from 2013 to 2016.
 ► Some measures of HIV-related behaviours including 
condomless sex, post-exposure prophylaxis, and HIV testing 
have also increased between 2013 and 2016.
 ► There is a need for improved monitoring to assess changing 
patterns of recreational drug use and associated behaviours 
so that sexual health services are able to anticipate and 
provide holistic care for their clients.
limitations
We recognise the different proportions in non-response between 
the AURAH and AURAH2 study could bias the comparison, and 
unfortunately data were not collected on the characteristics of 
non-responders to limit this. We also acknowledge a certain 
degree of selection bias may have occurred during recruitment 
to both studies. We further recognise that in our results, the 
reporting of drugs associated with chemsex does not necessarily 
equate to use of drugs during sex; however, previous data have 
shown that 75% of mephedrone and 85% of GHB/GBL users 
said they used the drugs solely to facilitate sex,32 although the 
use of drugs outside of a sexual setting, such as in a social or 
clubbing environment, is also important to consider. Addition-
ally, the results from the AURAH and AURAH2 studies may not 
be directly generalisable to the broader MSM population due 
to the sample of men being solely from sexual health clinics in 
London and Brighton, which have large gay communities, and 
may not reflect behaviour and lifestyle choices of clinic attendees 
in the wider community. In contrast to non-clinic attendees, 
and given the strong associations between sexual behaviour 
and recreational drug use, MSM who voluntarily attend sexual 
health clinics may have self-identified a need for sexual health 
screening, which could explain the associated higher prevalence 
of recreational drug use in this group. Furthermore, two of the 
clinics that participated in the AURAH and AURAH2 studies, 
56 Dean Street and Mortimer Market Clinic, are specialist 
centres of chemsex support where chemsex awareness is robust 
and specific psychosocial interventions are offered frequently 
to high-risk MSM. The increased awareness and community 
engagement around chemsex within these two clinics may have 
resulted in a larger proportion of those engaging in chemsex 
opting to attend them, which may also account for an overesti-
mation. However, it is also possible that some MSM not engaged 
with clinics may not test for HIV and STIs through perceived 
stigma or fear related to higher-risk sexual behaviours and or 
recreational drug use, and therefore our results could potentially 
underestimate the true prevalence of both.
COnClusIOns
There have been significant changes in use of drugs associated 
with chemsex and specific drug use, as well as increases across 
measures of HIV-related behaviours among HIV-negative MSM 
in the AURAH and AURAH2 study. Despite the decline in HIV 
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diagnoses in some London clinics, our results demonstrate 
the increasingly complex needs of MSM attending clinics for 
sexual healthcare, lifestyle support and health promotion. There 
remains a clear need for investment to adequately resource and 
support sexual health clinics to collaborate with specialised drug 
services to provide appropriate care that encompasses recre-
ational drug use as well as sexual health.
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